发布时间：2008.4

摘要

Countries covered: Taiwan

Taiwan represents a pharmaceutical market of moderate interest to multinational pharmaceutical firms
operating in the Asia Pacific region. The draws of the US$4.32bn market include a traditional preference
for branded medicines, a strong research environment - especially in the field of biotechnology - and a
highly urbanised population. However, several recent price cuts and a less than clear operating
environment provide a degree of concern. Consequently, Taiwan retains seventh position in BMI’s
Pharmaceutical Business Environment Ranking table for Q208 out of the 14 regional markets surveyed.
While BMI is expecting reasonable market growth, to around US$5.29bn by 2012, considerable
challenges will be presented by the new regulatory requirements. In November 2007, Taiwan introduced
a health technology assessment (HTA) system for pricing and reimbursement of new drugs. Specifically,
prior to evidence evaluation, the proposed price of a new pharmaceutical will be benchmarked using
existing prices in 10 other markets. HTA tools will then be employed to mark up or mark down that price,
depending on efficacy. While the programme aims to improve patient outcomes - as well as make muchneeded
savings in the public sector - similar systems in other countries have at times been accused of
having the opposite effect.


In the meantime, Taiwan is working on adoption of internationally recognised standards modelled on the
Pharmaceutical Inspection Co-operation Scheme (PIC/S). The programme will improve the quality of
medicines produced locally, and consequently their export potential. Full compliance is expected by the
end of 2009 at the latest, with membership of PIC/S - albeit not full, due to political pressure from China
- being a clear indication of the maturity of a country's pharmaceutical industry.


Taiwan's US$1.86bn medical device sector, which is poised to expand steadily over the next five years,
continues to be dynamic. In February 2008, US medical device manufacturer Ingen Technologies signed
a distribution agreement with Hong Kong-based Progressive International Holding (PIHK), which
covers Taiwan. The agreement concerns the distribution of Ingen’s proprietary product OxyView, a
device used to increase accuracy of medical care and prevent unnecessary medical costs. Shortly before
the announcement, US-based Merck & Co indicated that it is to base its new Asia Technology Training
Center in Taiwan.

目录及图表

Executive Summary

Taiwan Pharmaceuticals And Healthcare Industry SWOT

Taiwan Political SWOT

Taiwan Economic SWOT

Taiwan Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Pharmaceutical Business Environment Ratings

Limits Of Potential Returns

Risks To Realisation Of Returns

Taiwan - Market Summary

Regulatory Regime

Table: Examples Of Controlled Drugs In Taiwan

Medicine Categories In Taiwan

Recent Regulatory Developments

Intellectual Property Regime

Table: USTR Special 301 Report

Intellectual Property Developments

Compulsory Licensing

Pricing Regime

Price Cuts

Reimbursement Regime

Table: Drug Reimbursement Principles

Recent Reimbursement Developments

Free Trade Agreements

Industry Trends And Developments

Epidemiology

Healthcare System

Table: Premium Contribution For Taiwan's Bureau Of National Health Insurance (% share)

Domestic Pharmaceutical Sector

Table: Selected Local Industry Players

Foreign Company Activity

Medical Devices

Table: Taiwan Medical Device Market Forecast (US$bn unless otherwise stated)

Recent Developments In The Medical Devices Market

Biotechnology Sector

Recent Biotechnology Developments

Vaccines

Recent Developments In The Vaccines Market

Traditional Chinese Medicine

Industry Forecast Sce41

Overall Market Forecast

Table: Drug Expenditure And Prescription Market Indicators (US$mn unless otherwise stated)

Key Growth Factors - Industry

Table: Taiwan’s Health Expenditure Forecast Indicators

Key Growth Factors - Macroeconomic

Table: Taiwan - Economic Activity

Patented Market Forecast

Table: Taiwan’s Patented Drug Market Indicators

Generics Market Forecasts

Table: Taiwan’s Generics Market Indicators

OTC Market Forecast

Table: Taiwan’s OTC Market Forecast Indicators (US$mn unless otherwise stated)

Export/Import Forecasts

Table: Taiwan’s Trade Indicators (US$mn)

Other Healthcare Data Forecasts

Table: Other Healthcare Data Trends

Key Risks To BMI’s Forecast Scenario

Competitive Landscape.56

Table: Taiwan’s Pharmaceutical Market In Q406

Company Profiles

Multinationals

Pfizer

Sanofi-Aventis

GlaxoSmithKline

Novartis

Merck & Co

Bayer Schering Pharma

Indigenous Manufacturers

Yung Shin Pharmaceutical (YSP)

ScinoPharm Taiwan

Synmosa Biopharma

Life Star Pharmaceutical

EMO Biomedicine Corporation

Empax Pharma

Purzer Pharmaceutical

Taiwan Biotech Co

BMI Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources